{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:49:12Z","timestamp":1791571752302,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.numecd.2026.104822","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:32:54Z","timestamp":1780720374000},"page":"104822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of add-on PCSK9 inhibitors on endocan and arterial stiffness in heterozygous familial hypercholesterolemia: a two-lipid center real-world study"],"prefix":"10.1016","volume":"36","author":[{"given":"Arianna","family":"Toscano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giosiana","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Giacomo Barbagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Scilletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Di Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Piro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Scuruchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Squadrito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7023-3649","authenticated-orcid":false,"given":"Roberto","family":"Scicali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mandraffino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2026.104822_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.numecd.2017.07.003","article-title":"Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: clinical, genetic and atherosclerotic burden profile","volume":"28","author":"Scicali","year":"2018","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2026.104822_bib2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.numecd.2024.05.002","article-title":"Consensus document on diagnosis and management of familial hypercholesterolemia from the Italian Society for the Study of Atherosclerosis (SISA)","volume":"34","author":"Tarugi","year":"2024","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2026.104822_bib3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.numecd.2026.104822_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.798699","article-title":"Endocan: a key player of cardiovascular disease","volume":"8","author":"Chen","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.numecd.2026.104822_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbcan.2005.08.004","article-title":"Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy","volume":"1765","author":"Sarrazin","year":"2006","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.numecd.2026.104822_bib6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.niox.2021.09.006","article-title":"Endocan alters nitric oxide production in endothelial cells by targeting AKT\/eNOS and NFkB\/iNOS signaling","volume":"117","author":"Kumar","year":"2021","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.numecd.2026.104822_bib7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13643-025-02858-4","article-title":"The predictive value of endocan as a novel biomarker: an umbrella study on meta-analyses","volume":"14","author":"Nayak","year":"2025","journal-title":"Syst Rev"},{"key":"10.1016\/j.numecd.2026.104822_bib8","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehq165","article-title":"Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: \u2018establishing normal and reference values","volume":"31","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104822_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2025.104013","article-title":"Association between remnant cholesterol and arterial stiffness: evidence from NHANES 1999\u20132018","volume":"35","author":"Lai","year":"2025","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2026.104822_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jacl.2020.01.015","article-title":"Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: a two\u2013lipid center real-world experience","volume":"14","author":"Mandraffino","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2026.104822_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.pcad.2025.05.008","article-title":"Effect of inclisiran on lipid and mechanical vascular profiles in familial hypercholesterolemia subjects: results from a single lipid center real-world experience","author":"Bosco","year":"2025","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2026.104822_bib12","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1016\/j.numecd.2021.08.034","article-title":"Impact of high neutrophil-to-lymphocyte ratio on the cardiovascular benefit of PCSK9 inhibitors in familial hypercholesterolemia subjects with atherosclerotic cardiovascular disease: Real-world data from two lipid units","volume":"31","author":"Scicali","year":"2021","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2026.104822_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104822_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv370","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","author":"Kastelein","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104822_bib15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2026.104822_bib16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/HJH.0b013e32834fa8b0","article-title":"Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity","volume":"30","author":"Van Bortel","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.numecd.2026.104822_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jacl.2020.01.015","article-title":"Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: a two\u2013lipid center real-world experience","volume":"14","author":"Mandraffino","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2026.104822_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14269","article-title":"Effect of adding PCSK9 inhibitors to lipid\u2010lowering interventions on arterial stiffness: a systematic review and meta\u2010analysis","volume":"54","author":"Cavero\u2010Redondo","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.numecd.2026.104822_bib19","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/biom12040562","article-title":"PCSK9 plasma levels are associated with mechanical vascular impairment in familial hypercholesterolemia subjects without a history of atherosclerotic cardiovascular disease: results of six-month Add-On PCSK9 inhibitor therapy","volume":"12","author":"Toscano","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.numecd.2026.104822_bib20","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1186\/s12967-025-07432-z","article-title":"Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects","volume":"23","author":"Bosco","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.numecd.2026.104822_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.thromres.2020.07.049","article-title":"Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy","volume":"194","author":"Di Minno","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.numecd.2026.104822_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.numecd.2025.104215","article-title":"Translational biomarkers for integrated cardiovascular disease risk assessment: a multidisciplinary review with applications in precision medicine","volume":"35","author":"Visioli","year":"2025","journal-title":"Nutr Metabol Cardiovasc Dis"},{"key":"10.1016\/j.numecd.2026.104822_bib23","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093947532600284X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093947532600284X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:53:25Z","timestamp":1791568405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093947532600284X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S093947532600284X"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104822","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of add-on PCSK9 inhibitors on endocan and arterial stiffness in heterozygous familial hypercholesterolemia: a two-lipid center real-world study","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University.","name":"copyright","label":"Copyright"}],"article-number":"104822"}}